{
  "docId": "019de072-e6c6-771e-b24a-5adaac3cef4b",
  "docSlug": "1c626f0801e0e9ad1e805f8e0140c291",
  "documentTitle": "Alkermes | Results Presentation Deck | 26 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 26,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "RP2D stands for Recommended Phase 2 Dose.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e6c6-771e-b24a-5adaac3cef4b/8",
  "deckHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b",
  "deckJsonHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b.json",
  "deckAnchorHref": "/decks/019de072-e6c6-771e-b24a-5adaac3cef4b#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.235
      },
      "kind": "list",
      "text": "Establish pharmacokinetic/pharmacodynamic profile and determine RP2D; Demonstrate anti-tumor efficacy as monotherapy; Demonstrate anti-tumor efficacy in combination with pembrolizumab; Confirm differentiated safety and tolerability profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d3b1dcf-d061-47b1-aaa0-03bd20212c5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "RP2D, Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8c28fdc-fdd0-4fdc-9ee5-a49b45dab0e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "ARTISTRY-1: Designed to Characterize the Pharmacodynamic and Anti-Tumor Profile of IV Nemvaleukin",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "487ee20e-e0b8-4389-bc98-1cce43bb41b6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 7,
      "beatId": "423e1d79-de5e-4dfb-b4a5-e3f1fc39afdd",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 7-8 present Nemvaleukin Alfa as a potential solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}